Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells
Open Access
- 26 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e19892
Abstract
Cisplatin along with other platinum based drugs are some of the most widely used chemotherapeutic agents. However drug resistance is a major problem for the successful chemotherapeutic treatment of cancer. Current evidence suggests that drug resistance is a multifactorial problem due to changes in the expression levels and activity of a wide number of proteins. A majority of the studies to date have quantified mRNA levels between drug resistant and drug sensitive cell lines. Unfortunately mRNA levels do not always correlate with protein expression levels due to post-transcriptional changes in protein abundance. Therefore global quantitative proteomics screens are needed to identify the protein targets that are differentially expressed in drug resistant cell lines. Here we employ a quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels between cisplatin resistant (HeLa/CDDP) and sensitive HeLa cells in an unbiased fashion. A total of 856 proteins were identified and quantified, with 374 displaying significantly altered expression levels between the cell lines. Expression level data was then integrated with a network of protein-protein interactions, and biological pathways to obtain a systems level view of proteome changes which occur with cisplatin resistance. Several of these proteins have been previously implicated in resistance towards platinum-based and other drugs, while many represent new potential markers or therapeutic targets.Keywords
This publication has 57 references indexed in Scilit:
- Interactome Networks and Human DiseaseCell, 2011
- A guided tour of the Trans‐Proteomic PipelineProteomics, 2010
- How Common Are Extraribosomal Functions of Ribosomal Proteins?Molecular Cell, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Cathepsin D—Many functions of one aspartic proteaseCritical Reviews in Oncology/Hematology, 2008
- Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cellsSeminars in Cancer Biology, 2008
- Use of comparative proteomics to identify potential resistance mechanisms in cancer treatmentCancer Treatment Reviews, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- High-Speed Data Reduction, Feature Detection, and MS/MS Spectrum Quality Assessment of Shotgun Proteomics Data Sets Using High-Resolution Mass SpectrometryAnalytical Chemistry, 2007
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003